Got a Question?
If you have a question for our guest, host or DRG please submit it here.
To know COVID-19 is to know medicine
Guest: Dr RJ Tesi, CEO of INmune Bio
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Dr RJ Tesi, CEO of INmune Bio about its clinical program that seeks to determine whether its existing TNF inhibitors can be repurposed to prevents complications of cytokine storm caused by COVID-19. Dr Tesi gives solemn insight into trial design, endpoint selection, FDA application as well explaining how INmune is “messing” with the pathology of COVID-19, not only to treat its symptoms but to treat the disease itself. Dr Tesi takes us through the evolving landscape of secondary complications caused by COVID-19 and leaves us with the anecdote that many in the industry are beginning to understand; “to know COVID-19 is to know medicine”.
About our Guest
Dr RJ Tesi, CEO of INmune Bio
Dr. Tesi has been President, Chief Executive Officer and acting Chief Medical Officer since the formation of INmune Bio, Inc. in September 2015. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.
